Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. Treatment for Alzheimer’s disease.
In fact, What if detecting Alzheimer’s was as simple as getting a blood test? Our work is complex, risky, labor-intensive, persistent and expensive. Target Indication. It is unlikely that any one drug will successfully treat Alzheimer's disease. Our mission is to detect and treat Alzheimer’s disease.What if detecting Alzheimer’s was as simple as getting a blood test? We translate novel scientific insights into new medicines.
Cassava Sciences claims the protection of the Safe Harbor for forward-looking statements contained in the Act.
Together, we are setting a new course to develop therapies that can help improve human health. In Q2 2020, Cassava Sciences completed a randomized, placebo-controlled, double-blind study of its lead drug candidate, PTI-125, in patients with mild-to-moderate Alzheimer’s disease (N=64). In Q2 2020, Cassava Sciences completed a randomized, placebo-controlled, double-blind study of its lead drug candidate, PTI-125, in patients with mild-to-moderate Alzheimer’s disease (N=64). It requires collaboration.The National Institutes of Health (NIH) continues to provide our research programs with substantial scientific and financial support.
All this makes the case to consider the development of new and promising approaches for the treatment and diagnosis of Alzheimer's disease.
Academics and scientific and medical advisors supply us with substantial technical support. Description. Studies. The National Institutes of Health (NIH) continues to provide … A key focus of our R&D is to develop first-in-class medicines for people with debilitating neurodegenerative conditions. Phase 2b Study - on-going. Cassava Sciences Announces Full-year 2019 Financial Results and Anticipated Key Milestones for 2020 GlobeNewswire Inc. - 3/26/2020 8:15:10 AM: Cassava Sciences Announces Initiation of an Open-Label Study to Evaluate PTI-125 in Patients with Alzheimer’s Disease GlobeNewswire Inc. - 3/25/2020 8:15:10 AM Unraveling Alzheimer's disease is a hard problem.
Collaboration is key.
PTI-125.
Antibody-based diagnostic system.
It is unlikely that any one drug will successfully treat Alzheimer's disease.All this makes the case to consider the development of new and promising approaches for the treatment and diagnosis of Alzheimer's disease.Unraveling Alzheimer's disease is a hard problem. {{ article.date }} {{ article.time }} It requires collaboration. Over 5 million people have Alzheimer's disease in the U.S. today.
Cassava Sciences owns worldwide rights to its pipeline, without royalty or milestone obligations. Detection of …
Pivotal. Development Status. This study was substantially funded by a research grant award from the National Institutes of Health (NIH).
... Trevena Announces FDA Approval of OLINVYK (oliceridine) injection . • {{ article.symbol }} • We’re working on that too.The National Institutes of Health (NIH) is providing substantial scientific and financial support for our research programs in neurodegeneration.We are a clinical-stage biopharmaceutical company focused on neuroscience. SavaDx. A long-prevailing scientific hypothesis - clearing amyloid from the brain - has led to high-profile clinical failures.
Phase 2a Study - positive results announced 2019. Product Candidate.
• {{ article.symbol }} •
This number will increase significantly in the years ahead.
{{ article.date }} {{ article.time }} That’s a drastic challenge. New drugs for Alzheimer's remain elusive. FDA approval coming and low/NO Float. Proprietary, oral, small molecule drug.